|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.50 USD | -1.30% |
|
+2.06% | -1.56% |
| 08/04 | Viking Therapeutics May Benefit From New Era for Weight Loss Pills, Oppenheimer Says | MT |
| 01/04 | Lilly gains after FDA approves weight-loss pill, sizing down investor doubts | RE |
| Capitalization | 405.05Cr 346.24Cr 320.05Cr 301.76Cr 559.97Cr 37TCr 572.82Cr 3.78TCr 1.47TCr 18TCr 1.52TCr 1.49TCr 64TCr | P/E ratio 2026 * |
-8.23x | P/E ratio 2027 * | -7.55x |
|---|---|---|---|---|---|
| Enterprise value | 361.2Cr 308.75Cr 285.4Cr 269.09Cr 499.35Cr 33TCr 510.81Cr 3.37TCr 1.31TCr 16TCr 1.36TCr 1.33TCr 57TCr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
92.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Viking Therapeutics, Inc.
| 1 day | -1.37% | ||
| 1 week | +2.06% | ||
| Current month | +6.42% | ||
| 1 month | -0.09% | ||
| 3 months | +9.04% | ||
| 6 months | +3.19% | ||
| Current year | -1.56% |
| 1 week | 32.6 |  | 35.46 |
| 1 month | 29.88 | | 37.5 |
| Current year | 25.77 | | 37.5 |
| 1 year | 21.21 | | 43.15 |
| 3 years | 8.28 | | 99.41 |
| 5 years | 2.02 | | 99.41 |
| 10 years | 0.88 | | 99.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Lian
CEO | Chief Executive Officer | 60 | 24/09/2012 |
Gregory Zante
DFI | Director of Finance/CFO | 55 | 04/01/2021 |
Marianne Mancini
COO | Chief Operating Officer | 61 | 04/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Lawson Macartney
CHM | Chairman | 68 | 01/05/2015 |
Brian Lian
CHM | Chairman | 60 | 24/09/2012 |
Matthew Foehr
BRD | Director/Board Member | 53 | 01/05/2014 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -5.90% | 0% | 293,477 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.30% | +2.06% | +60.92% | +104.43% | 405.05Cr | |
| +0.80% | +5.15% | +39.70% | +97.05% | 4.92TCr | |
| +0.13% | +3.04% | +107.47% | +26.86% | 4.68TCr | |
| -2.53% | -4.94% | +140.27% | +827.46% | 3.44TCr | |
| +1.70% | +2.43% | +0.41% | -26.79% | 2.33TCr | |
| +1.01% | +2.63% | +94.05% | -24.18% | 1.88TCr | |
| -0.69% | +2.20% | +47.08% | -32.55% | 1.73TCr | |
| +1.99% | -1.64% | +94.24% | +213.73% | 1.59TCr | |
| +1.53% | +4.41% | -3.15% | +1,175.49% | 1.5TCr | |
| +1.61% | -2.09% | +85.62% | - | 1.44TCr | |
| Average | +0.40% | +0.70% | +66.66% | +262.39% | 2.39TCr | |
| Weighted average by Cap. | +0.30% | +1.84% | +72.51% | +241.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -50Cr -43Cr -40Cr -37Cr -69Cr -4.63TCr -71Cr -467Cr -182.09Cr -2.23TCr -187.89Cr -183.91Cr -7.97TCr | -58Cr -50Cr -46Cr -43Cr -80Cr -5.37TCr -82Cr -542.22Cr -211.42Cr -2.59TCr -218.16Cr -213.54Cr -9.25TCr |
| Net Debt | -44Cr -37Cr -35Cr -33Cr -61Cr -4.05TCr -62Cr -409Cr -159.47Cr -1.95TCr -164.56Cr -161.07Cr -6.98TCr | -52Cr -44Cr -41Cr -39Cr -72Cr -4.79TCr -73Cr -484.01Cr -188.72Cr -2.31TCr -194.73Cr -190.61Cr -8.26TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | 34.62 $ | -0.94% | 6,82,215 |
| 09/26/09 | 34.95 $ | +3.80% | 20,64,177 |
| 08/26/08 | 33.67 $ | -0.09% | 17,94,272 |
| 07/26/07 | 33.70 $ | -0.68% | 14,90,133 |
| 06/26/06 | 33.93 $ | -2.50% | 23,94,115 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VKTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition